Laura Nuño1, Beatriz Joven2, Patricia Carreira2, Valentina Maldonado3, Carmen Larena3, Irene Llorente4, Eva Tomero4, María Carmen Barbadillo5, Paloma García-de la Peña6, Lucía Ruiz7, Juan Carlos López-Robledillo7, Henry Moruno8, Ana Pérez8, Tatiana Cobo-Ibáñez9, Raquel Almodóvar10, Leticia Lojo11, Indalecio Monteagudo12, María Jesús García-De Yébenes13, Francisco Javier López-Longo12. 1. Servicio de Reumatología, Hospital La Paz, Madrid, España. Electronic address: lauranuno2@hotmail.com. 2. Servicio de Reumatología, Hospital Doce de Octubre, Madrid, España. 3. Servicio de Reumatología, Hospital Ramón y Cajal, Madrid, España. 4. Servicio de Reumatología, Hospital La Princesa, Madrid, España. 5. Servicio de Reumatología, Hospital Puerta de Hierro, Madrid, España. 6. Servicio de Reumatología, Hospital Madrid Norte Sanchinarro, Madrid, España. 7. Servicio de Reumatología, Hospital Infantil Niño Jesús, Madrid, España. 8. Servicio de Reumatología, Hospital Príncipe de Asturias, Madrid, España. 9. Servicio de Reumatología, Hospital Infanta Sofía, Madrid, España. 10. Servicio de Reumatología, Hospital Fundación Alcorcón, Madrid, España. 11. Servicio de Reumatología, Hospital Infanta Leonor, Madrid, España. 12. Servicio de Reumatología, Hospital Gregorio Marañón, Madrid, España. 13. Instituto de Salud Musculoesquelética, Madrid, España.
Abstract
OBJECTIVE: To analyze clinical characteristics, survival and causes of death of patients diagnosed with autoimmune inflammatory myositis in the REMICAM registry from the Society of Rheumatology in the Community of Madrid (SORCOM). METHODS: Multicenter cohort of patients diagnosed with autoimmune inflammatory myopathy with follow-up between January 1980 and December 2014. A total of 313 variables concerning demographic, clinical and morbidity data were collected, and a comparison was performed between clinical subgroups. RESULTS: A total of 479 patients were recruited from 12 centers, with 14% of patients lost to follow-up. Seventy-four percent of cases were women, age at diagnosis of 44±23 years and a mean follow-up period of 10±8 years. The most frequent clinical subgroups were primary myositis (PM 29%, DM 22%), followed by overlap myositis (20.5%), juvenile myositis (18%), myositis associated with cancer (8%), immune-mediated necrotizing myositis (1%) and inclusion body myositis (1%). During the follow-up period, a total of 114 deaths (28%) were registered, the main causes being cancer (24%), infections (23%) and cardiovascular events (21%). CONCLUSIONS: A total of 479 patients were recruited in the REMICAM registry of inflammatory myopathies. Including sociodemographic, clinical and prognostic information, it represents the largest Spanish multicenter registry to date in rheumatology, and constitutes an important source for conducting further substudies.
OBJECTIVE: To analyze clinical characteristics, survival and causes of death of patients diagnosed with autoimmune inflammatory myositis in the REMICAM registry from the Society of Rheumatology in the Community of Madrid (SORCOM). METHODS: Multicenter cohort of patients diagnosed with autoimmune inflammatory myopathy with follow-up between January 1980 and December 2014. A total of 313 variables concerning demographic, clinical and morbidity data were collected, and a comparison was performed between clinical subgroups. RESULTS: A total of 479 patients were recruited from 12 centers, with 14% of patients lost to follow-up. Seventy-four percent of cases were women, age at diagnosis of 44±23 years and a mean follow-up period of 10±8 years. The most frequent clinical subgroups were primary myositis (PM 29%, DM 22%), followed by overlap myositis (20.5%), juvenile myositis (18%), myositis associated with cancer (8%), immune-mediated necrotizing myositis (1%) and inclusion body myositis (1%). During the follow-up period, a total of 114 deaths (28%) were registered, the main causes being cancer (24%), infections (23%) and cardiovascular events (21%). CONCLUSIONS: A total of 479 patients were recruited in the REMICAM registry of inflammatory myopathies. Including sociodemographic, clinical and prognostic information, it represents the largest Spanish multicenter registry to date in rheumatology, and constitutes an important source for conducting further substudies.
Authors: Luis Fernando Valladales-Restrepo; Ana Camila Delgado-Araujo; Brayan Stiven Aristizábal-Carmona; Lina María Saldarriaga-Rivera; Jorge Enrique Machado-Alba Journal: Int J Rheumatol Date: 2022-07-05
Authors: Laura Nuño-Nuño; Beatriz Esther Joven; Patricia E Carreira; Valentina Maldonado-Romero; Carmen Larena-Grijalba; Irene Llorente Cubas; Eva Gloria Tomero; María Carmen Barbadillo-Mateos; Paloma García De la Peña Lefebvre; Lucía Ruiz-Gutiérrez; Juan Carlos López-Robledillo; Henry Moruno-Cruz; Ana Pérez; Tatiana Cobo-Ibáñez; Raquel Almodóvar González; Leticia Lojo; María Jesús García De Yébenes; Francisco Javier López-Longo Journal: Rheumatol Int Date: 2017-09-02 Impact factor: 2.631